AmCad BioMed Receivables

The latest receivables for 4188.TWO is $5.2M as of June 2026. That compares with $10M in the prior-year period — down 48.6% year over year. Investors often review this figure alongside AmCad BioMed's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4188.TWO's receivables moved from $10M to $5.2M — a 48.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AmCad BioMed's operating scale or balance-sheet position.

A receivables figure of $5.2M for 4188.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4188.TWO's receivables ($5.2M), review year-over-year change from $10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.